Chelsea Therapeutics Intl Ltd fka CHIP

[Noonehasthisusername]

FDA APPROVES CHELSEA'S (CHTP) NORTHERA. WEDBUSH KEEPS OUTPERFORM, $8 TARGETFont size: A | A | A
undefined undefined | S&P Capital IQ
SNPMarketScopeViewsNews2014-02-19 11:09:15.000CHTPCHELSEA THERAPEUTICS INTERNATIONAL LTD.BRIAN EGLIFDA APPROVES CHELSEA'S (CHTP) NORTHERA. WEDBUSH KEEPS OUTPERFORM, $8 TARGET Analyst Liana Moussatos tells salesforce FDA approved Northera for treatment of symptomatic neurogenic orthostatic hypotension under accelerated approval program. Notes while label indicates effectiveness beyond 2 weeks of treatment hasn't yet been shown, it doesn't restrict duration of use, which is positive for commercialization. Says FDA's accelerated approval program allows for conditional approval of drug that fills serious unmet medical need, provided add'l confirmatory studies are conducted. With approval sees potential partnership or acquisition for co. B.Egli|US;CHTP|87899|US|2534836

----

I like the potential acquisition language.